AURKA and glioblastoma: While this was a limitation of the current investigation, analyzing the impact of Alisertib on PD-L1 expression in this glioblastoma model and further assessing the effects of AURKA inhibition in combination with PD-1/PD-L1 blockade is an important next step to more comprehensively elucidate the complex relationship between these critical signaling pathways in the context of this highly aggressive brain cancer.